Riskpilot← Back to searchSign inGet full accessBiognos AB
ABActiveOrg 5567555890Generatorsgatan 1Research and experimental development on natural sciences and engineering · NACE 7210Est. 20081 employees
Revenue 2024
SEK 95K
EBITDA margin
-904.2%
+29% vs 2023
Equity ratio
50.7%
Financial strength
Net profit 2024
SEK -859K
+29% vs 2023
| Revenue | SEK 95K | — |
| EBITDA | SEK -859K | +29% |
| Net profit | SEK -859K | +29% |
| Total assets | SEK 2,6M | +334% |
| Equity | SEK 1,3M | +620% |
| Employees | 1 | — |
Legal name
Biognos AB
Org number
5567555890
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
9 april 2008
Share capital
SEK 100 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolagets verksamhet ska bestå av konsultverksamhet inom datorstödd läkemedelsutveckling, bioteknisk verksamhet, förvaltning av immateriella rättigheter, utveckling och handel avseende dataprogram, samt därmed förenlig verksamhet.
Address
Generatorsgatan 1
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 967 | 977 | 128 | 0 | 95 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −389 | −247 | −1 266 | −1 211 | −859 |
| Depreciation & amort. | −43 | −31 | −19 | −7 | −0 |
| EBIT | −432 | −278 | −1 285 | −1 218 | −859 |
| Net financials | — | — | −2 | — | — |
| Profit before tax | 1 | −279 | −1 287 | −1 218 | −859 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 1 | −279 | −1 287 | −1 218 | −859 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 701 | 518 | 584 | 602 | 2 614 |
| Equity | 67 | 88 | 201 | 184 | 1 325 |
| Long-term debt | 0 | 0 | 0 | 1 | 971 |
| Short-term debt | 634 | 429 | 383 | 417 | 318 |
| Total debt | 634 | 429 | 383 | 418 | 1 289 |
EBITDA margin
-904.2%
This company
15.8%
Market median
-5823% vs market
20202024
Equity ratio
50.7%
This company
38.2%
Market median
+33% vs market
20202024
Return on equity
-64.8%
This company
18.4%
Market median
-452% vs market
20202024
Net profit margin
-904.2%
This company
8.1%
Market median
-11263% vs market
20202024
Asset turnover
0.04×
This company
1.12×
Market median
-96% vs market
20202024
Debt / equity
0.97×
This company
0.62×
Market median
+56% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
CE Chief Auditor | Chief Auditor | 2022 |
| Former (1) | ||
MF Chief Auditor | Chief Auditor | 2022 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NiPeg Invest AB
Biognos AB Board members of Biognos AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Emil Fredrik Boberg | Chief Auditor | 0 companies |
| Magnus Fjellman | Chief Auditor | 0 companies |
| Per-Georg Nyholm | Board of Directors | 0 companies |
| Nina Louise Viktoria Granath | Deputy Board Member | 0 companies |